Gut bugs may hold key to stomach cancer treatment success

NCT ID NCT07400354

Recruiting now Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether the bacteria in your gut can predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. Researchers will track 300 patients and check their gut bacteria at several points during treatment. The goal is to find a way to personalize treatment based on each person's unique gut microbiome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients with metastatic gastric cancer will benefit most from combining immunotherapy with chemotherapy, leading to more personalized treatment.
What could go wrong: This is an early exploratory study, not a treatment trial. It aims to find a predictive marker, not to test a new cure. The results may not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric carcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER GUT MICROBIOTA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.